THERAPEUTIC USE OF MONOCLONAL ANTIBODIES: GENERAL ASPECTS AND CHALLENGES FOR DRUG DELIVERY

DANIELA A. QUINTEROS; JOSÉ M. BERMÚDEZ; SOLEDAD RAVETTI; ALICIA CID; DANIEL A. ALLEMANDI; SANTIAGO D. PALMA

NANOSTRUCTURES FOR DRUG DELIVERY

ELSEVIER

Año: 2017; p. 807 - 833

Monoclonal antibodies are routinely used in several fields but the great challenge has been their use as therapeutic agents for the treatment of diseases such as breast cancer, leukaemia, asthma, macular degeneration, arthritis, Crohn´s disease and transplants among others.Monoclonal antibodies are protein molecules made in the laboratory from hybridoma cells by recombinant DNA technology.Important advances have been made over the past decade to improve some critical points such as safety and efficacy of the first generation of therapeutic antibodies.This type of molecules presents a significant challenge from the pharmaceutical point of view due to their characteristics such as molecular size, stability and solubility. In this review we have attempted to identify the major issues associated with therapeutics approaches, formulating drawbacks and delivering antibody drugs, particularly focused on the challenges and opportunities that these present for the future.